NASDAQ:HBIO - Harvard Bioscience Stock Price, Price Target & More

Harvard Bioscience trades on the NASDAQ under the ticker symbol "HBIO."

Harvard Bioscience, Inc. (NASDAQ:HBIO) released its quarterly earnings results on Wednesday, May, 2nd. The medical instruments supplier reported $0.03 earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of $0.03. The medical instruments supplier had revenue of $26.76 million for the quarter, compared to analyst estimates of $27.50 million. Harvard Bioscience had a positive return on equity of 2.79% and a negative net margin of 3.70%. View Harvard Bioscience's Earnings History.

Harvard Bioscience is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for Harvard Bioscience.

2 brokerages have issued 1-year price targets for Harvard Bioscience's stock. Their predictions range from $8.00 to $11.00. On average, they expect Harvard Bioscience's share price to reach $9.50 in the next year. This suggests a possible upside of 84.5% from the stock's current price. View Analyst Ratings for Harvard Bioscience.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harvard Bioscience in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Harvard Bioscience include Pacific Biosciences of California (PACB), Quanterix (QTRX), Fluidigm (FLDM), Eyepoint Pharmaceuticals (EYPT), HTG Molecular Diagnostics (HTGM), Arrayit Corp common stock (ARYC), Aethlon Medical (AEMD), Precipio (PRPO), Pressure Biosciences (PBIO), Scientific Industries (SCND) and PositiveID (PSID).

Media coverage about HBIO stock has trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Harvard Bioscience earned a coverage optimism score of 0.13 on Accern's scale. They also gave media coverage about the medical instruments supplier an impact score of 46.76 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Shares of HBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of HBIO stock can currently be purchased for approximately $5.15.

Harvard Bioscience has a market capitalization of $185.30 million and generates $101.88 million in revenue each year. The medical instruments supplier earns $-860,000.00 in net income (profit) each year or $0.05 on an earnings per share basis. Harvard Bioscience employs 434 workers across the globe.

Harvard Bioscience's mailing address is 84 OCTOBER HILL ROAD, HOLLISTON MA, 01746. The medical instruments supplier can be reached via phone at 508-893-8999 or via email at [email protected]